Journals / Turkish Journal of Medical Sciences / 2014 / Cilt: 44 - Sayı: 4

Pharmacological profile of a nitric oxide donor spermine NONOate in the mouse corpus cavernosum

Pages
569–575
Publication Date
2014-05-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Spermine NONOate may be considered an attractive treatment for erectile dysfunction in pathologic disorders with a lack of endogenous NO production.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:To investigate the effects of spermine NONOate in the cavernous tissue obtained from mice treated or untreated with sildenafil.
📊
Key Findings & Data:Materials and methods: We studied the effects of spermine NONOate on the tone and nitrergic relaxation responses of isolated mouse corpus cavernosum and compared them with sodium nitroprusside in the absence or presence of L-nitroarginine, hydroxocobalamin, pyrogallol, diethyldithiocarbamate (DETCA), or 1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one (ODQ).
💡
Conclusion & Impact:Spermine NONOate may be considered an attractive treatment for erectile dysfunction in pathologic disorders with a lack of endogenous NO production.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Key words: EFS · electrical field stimulation · L-NOARG

Abstract

To investigate the effects of spermine NONOate in the cavernous tissue obtained from mice treated or untreated with sildenafil. Materials and methods: We studied the effects of spermine NONOate on the tone and nitrergic relaxation responses of isolated mouse corpus cavernosum and compared them with sodium nitroprusside in the absence or presence of L-nitroarginine, hydroxocobalamin, pyrogallol, diethyldithiocarbamate (DETCA), or 1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one (ODQ). The neurogenic contractions and relaxations of the tissues were induced by electrical field stimulation. Some mice received a single oral dose of sildenafil and after 1 h the effects of spermine NONOate were evaluated by in vitro studies. Results: Spermine NONOate relaxed mouse corpus cavernosum in a concentration-dependent manner. Spermine-NONOate-induced relaxation was relatively slow to develop and it was reversible and reproducible. These relaxations were significantly suppressed by hydroxocobalamin, diethyldithiocarbamate, or ODQ, but not by L-nitroarginine or pyrogallol. Spermine NONOate potentiated the nitrergic relaxations to electrical field stimulation (EFS), whereas it significantly reduced EFS-induced contractions. Sildenafil treatment can enhance the relaxant responses to spermine NONOate and EFS. Conclusion: These findings suggest that spermine NONOate has a potent relaxant action in cavernous tissue and this effect can be potentiated by oral sildenafil treatments. Spermine NONOate may be considered an attractive treatment for erectile dysfunction in pathologic disorders with a lack of endogenous NO production.

Özet

To investigate the effects of spermine NONOate in the cavernous tissue obtained from mice treated or untreated with sildenafil. Materials and methods: We studied the effects of spermine NONOate on the tone and nitrergic relaxation responses of isolated mouse corpus cavernosum and compared them with sodium nitroprusside in the absence or presence of L-nitroarginine, hydroxocobalamin, pyrogallol, diethyldithiocarbamate (DETCA), or 1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one (ODQ). The neurogenic contractions and relaxations of the tissues were induced by electrical field stimulation. Some mice received a single oral dose of sildenafil and after 1 h the effects of spermine NONOate were evaluated by in vitro studies. Results: Spermine NONOate relaxed mouse corpus cavernosum in a concentration-dependent manner. Spermine-NONOate-induced relaxation was relatively slow to develop and it was reversible and reproducible. These relaxations were significantly suppressed by hydroxocobalamin, diethyldithiocarbamate, or ODQ, but not by L-nitroarginine or pyrogallol. Spermine NONOate potentiated the nitrergic relaxations to electrical field stimulation (EFS), whereas it significantly reduced EFS-induced contractions. Sildenafil treatment can enhance the relaxant responses to spermine NONOate and EFS. Conclusion: These findings suggest that spermine NONOate has a potent relaxant action in cavernous tissue and this effect can be potentiated by oral sildenafil treatments. Spermine NONOate may be considered an attractive treatment for erectile dysfunction in pathologic disorders with a lack of endogenous NO production.

🔖

Cite This Article

ERTUĞ, F. P., ŞİNGİRİK, E., BÜYÜKNACAR, H. S., GÖÇMEN, C., SEÇİLMİŞ, M. A. (2014). Pharmacological profile of a nitric oxide donor spermine NONOate in the mouse corpus cavernosum. Turkish Journal of Medical Sciences, Cilt: 44 - Sayı: 4, 569–575. https://ajindex.com/articles/218254

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Saenz de Tejada I. Nitric oxide as a mediator of relaxation of the corpus cavernosum. N Engl J Med 1992; 326: 1638. Saenz de Tejada I. Therapeutic strategies for optimizing PDE-5 inhibitor therapy in patients with erectile dysfunction considered difficult or challenging to treat. Int J Impot Res 2004; 16: S40–S42. Ulvi H, Aygül R, Demir R. Effect of L-carnitine on diabetic neuropathy and ventricular dispersion in patients with diabetes mellitus. Turk J Med Sci 2010; 40: 169–175.
  2. Yalçınkakaya FR, Davarcı M, Akcin S, Gokce A, Guven EO, İnci M, Balbay MD. Urodynamic evaluation of acute effects of sildenafil on voiding among males with erectile dysfunction and symptomatic benign prostate. Turk J Med Sci 2012; 42: 951–995.
  3. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA, for The Sildenafil Study Group. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998; 338: 1397–1404.
  4. Ballard SA, Gingell CJ, Tang K, Turner LA, Price ME, Naylor AM. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol 1998; 159: 2164–2171.
  5. Saenz De Tejada I, Anglin G, Knight JR, Emmick JT. Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care 2002; 25: 2159–2164.
  6. Goldstein I, Young JM, Fıscher J, Bangerter K, Segerson T, Taylor T, The Vardenafil Diabetes Study Group. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes. Diabetes Care 2003; 26: 777–783.
  7. Friebe A, Koesling D. Mechanism of YC-1-induced activation of soluble guanylyl cyclase. Mol Pharmacol 1998; 53: 123–127.
  8. Kalsi JS, Rees RW, Hobbs AJ, Royle M, Kell1 PD, Ralph DJ, Moncado S, Cellek S. Bay41-2272, a novel nitric oxide independent soluble guanylate cyclase activator, relaxes human and rabbit corpus cavernosum in vitro. J Urol 2003; 169: 761–766.
  9. Salom JB, Barbera MD, Centeno JM, Orti M, Torregrosa G, Albroch E. Relaxant effects of sodium nitroprusside and NONOates in rabbit basilar artery. Pharmacol 1998; 57: 79–87.
  10. De Witt BJ, Marrone JR, Kaye AD, Keefer LK, Kadowitz PJ. Comparison of responses to novel nitric oxide donors in the feline pulmonary vascular bed. Eur J Pharmacol 2001; 430: 311–315.
  11. Keefer LK, Nims RW, Davies KM, Wink DA. “NONOates” (1-substituted diazen-1-ium-1,2-diolates) as nitric oxide donors: Convenient nitric oxide dosage forms. Methods Enzymol 1996; 268: 281–293.
  12. Göçmen C, B